Saturday, 20 July 2024

Australia's most trusted
source of pharma news

Saturday, 20 July 2024
Listen to this story 

Which pharmas need a refresh?

Posted 19 June 2024 AM

Some of the world's richest pharmas are earning the majority of their revenue from drugs that are over 10 years old and heading for patent expiry, but new analysis has exposed which companies have "freshened" their portfolios to replace that income when it disappears. 

Evaluate's 2024 Freshness Index: Who Needs to Freshen Up? looked at the Top 10 companies by revenue from both prescription and over-the-counter drugs in 2023 to find which pharma's revenues are the closest to the cliff and which companies need to freshen up.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (15)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (9)

Other (28)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.